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Progressive rod–cone degeneration (prcd) is a late-onset, autosomal recessive photoreceptor degeneration of dogs and a homolog for some
forms of human retinitis pigmentosa (RP). Previously, the disease-relevant interval was reduced to a 106-kb region on CFA9, and a common
phenotype-specific haplotype was identified in all affected dogs from several different breeds and breed varieties. Screening of a canine retinal
EST library identified partial cDNAs for novel candidate genes in the disease-relevant interval. The complete cDNA of one of these, PRCD, was
cloned in dog, human, and mouse. The gene codes for a 54-amino-acid (aa) protein in dog and human and a 53-aa protein in the mouse; the first 24
aa, coded for by exon 1, are highly conserved in 14 vertebrate species. A homozygous mutation (TGC → TAC) in the second codon shows
complete concordance with the disorder in 18 different dog breeds/breed varieties tested. The same homozygous mutation was identified in a
human patient from Bangladesh with autosomal recessive RP. Expression studies support the predominant expression of this gene in the retina,
with equal expression in the retinal pigment epithelium, photoreceptor, and ganglion cell layers. This study provides strong evidence that a
mutation in the novel gene PRCD is the cause of autosomal recessive retinal degeneration in both dogs and humans.
© 2006 Elsevier Inc. All rights reserved.Keywords: Dogs; Disease models, animal; Genetic diversity; Genetic linkage; Genetic markers; Genetic predisposition to disease; Genetic variation; Mutation;
Retinal degeneration; Retinitis pigmentosaProgressive rod–cone degeneration (prcd) is a canine, late-
onset, autosomal recessive photoreceptor degeneration of
unknown molecular etiology [1]. This disorder is one of
several inherited diseases grouped under the progressive
retinal atrophy (PRA) rubric. These serve as animal models
for human retinitis pigmentosa (RP) due to shared molecular
defects and/or phenotypic similarities (see [2] for review).
Together with the rd mouse and RCS rat, prcd represents one⁎ Corresponding author. Fax: +1 215 573 2162.
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doi:10.1016/j.ygeno.2006.07.007of the best characterized models of inherited retinal degenera-
tion (see [3–12]). Previously, the disease was mapped to the
centromeric end of canine chromosome 9 (CFA9), a region
orthologous to the telomeric end of human chromosome 17
(HSA17q22; [13,14]). A physical and radiation hybrid map of
the region confirmed the syntenic organization of the
homologous chromosomal segments, but demonstrated also
that the order of gene clusters, and genes within clusters,
differed between human and dog [15].
In a companion paper, we reported the use of linkage
disequilibrium (LD) analysis across several dog breeds
552 B. Zangerl et al. / Genomics 88 (2006) 551–563affected with prcd [2,9] to narrow the candidate region and
direct the positional cloning of prcd [16]. As individual dog
breeds represent genetic isolates, this powerful technique
reduced the critical interval from ∼6.4 Mb to 106 kb and
identified a chromosomal haplotype shared by 14 different dog
breeds or breed varieties [16]. This suggested that a common
ancestral chromosome containing the mutant gene was widely
distributed as modern dog breeds developed. The LD region,
flanked by AANAT and ST6GalNac1, is completely contained
in a single RPC181 BAC clone (10-M13; [17]; http://bacpac.
chori.org) and includes three known genes: CYGB, RHBDL,
and STHM (ST6GalNac2). All the genes in the interval were
evaluated and excluded from causative association with
disease [16].
In a complementary effort we created a normalized canine
retinal EST library that was catalogued by suggested gene
homology and chromosomal location [18]. Intended as a
means to identify and evaluate positional candidate genes
within the prcd interval, the combination of sequence and
expression data yielded several potential candidate genes in the
original disease-relevant interval. The application of this
approach on the final shared haplotype identified a mutation
in a novel gene of unknown function, referred to as progressive
rod–cone degeneration (PRCD). In this study, we report the
preliminary characterization of PRCD. Furthermore, we
analyzed samples from 1863 human patients with RP and
other inherited retinal disorders, whose diseases had been
previously excluded from causal association with genes known
to cause retinal degeneration (RetNet—Retinal Information
System; http://www.sph.uth.tmc.edu/RetNet/), and demonstrate
that the identical mutation that causes prcd in dogs is
homozygously present in a human RP patient.Fig. 1. Display of the prcd candidate region. (A) LD was used to reduce the candida
1131, 1365, and 3041). PRCD was cloned within orthologous regions in the (B) dog
structure.Results
Identification and characterization of PRCD
Identification of new candidate genes from a retinal EST
library
Although linkage analysis of prcd-informative pedigrees
mapped the disease locus to CFA9 [14], the original canine
genome sequence draft (http://www.genome.gov/11007358;
July 2004) suggested a translocation of the centromeric CFA9
region to CFA18. To establish the correct chromosomal position
of the disease interval, FISH hybridization was performed with
clones isolated from an 8× redundant dog genomic RPCI81BAC
library ([17]; http://bacpac.chori.org/) that are specific for CFA9
(189-B1) or are included in the physical map of the prcd interval
(429-O8; [15]). Both probes colocalized on the same canine
chromosome that was identified as CFA9 by the chromosome-
specific probe and G-banding pattern (data not shown). The
assignment of the prcd-critical interval to CFA9 was confirmed
in the new canine genome draft assembly ([19], May 2005 v2.0).
As presented in a companion paper [16], LD mapping
identified a common 106-kb candidate region on CFA9 flanked
by AANAT and ST6GalNac1. This interval, and flanking genes,
is contained in RPCI81 BAC 10-M13 and includes RefSeq
genes AANAT, RHBDL6, CYGB, ST6GalNac1,and ST6Gal-
Nac2, all of which were previously excluded from causative
association with disease. To complement the positional cloning
of prcd and begin characterization of the canine retinome, we
developed a normalized canine retinal cDNA library [18]
containing a total of 6316 retinally expressed clones that were
assembled into 3980 unique sequences, termed “contig,” with
unique identifier numbers (htpp://www.bioinformatics.upenn.te region to 106 kb [16]. This interval harbors three canine retinal ESTs (contigs
, (C) human, and (D) mouse and showed a high degree of conservation in gene
553B. Zangerl et al. / Genomics 88 (2006) 551–563edu/canine_retinalESTs/). BLASTN of those clones against the
3.2× low-pass genomic RPCI81 BAC 10-M13 sequence
produced significant alignment for three contig sequences,
1131, 1365, and 3041 (Fig. 1A). Contig 3041 represents five
exons of a previously deposited, unpublished gene (DN904971,
CF407776, CF407775, DN37851), and we found no sequence
changes in this gene between prcd-affected and normal dogs.
Cloning of PRCD
Contig sequences 1131 and 1365 are 1219 bp apart and were
assumed to represent a single gene (Fig. 1A). They did not have
a recognizable exon/intron structure and, as both are adjacent to
poly(A) stretches in the genomic DNA, could have represented
potential genomic contamination of the EST library. Compar-
ison between the canine, human, and mouse genomic and
cDNA sequences identified potential orthologous genes con-
served in these species and a suggested translation site
approximately 6 kb upstream of contig 1131 (Figs. 1B–D).
This was confirmed by RT-PCR from retinal RNA and resulted
in cloning of the full-length ORF in all three species.
Canine PRCD was first partially retrieved utilizing primers
designed from contig 1131 and predicted exons 1 and 2, extended
by 5′ and 3′ RACE, and the most common retinal transcript was
confirmed by RT-PCR (695 bp, four exons; Accession No.
DQ390330). Additional splice variants were obtained during the
cloning process (Accession Nos. DQ390331, DQ390332,
DQ390333, DQ390334, DQ390335, DQ390336). RT-PCR
from human retina yielded a 417-bp product spanning four
exons (Accession No. DQ390338, Fig. 1C); the sequence
confirms hypothetical LOC400621, for which 20% of the total
expression has been estimated to be present in the eye (http://
genome-www5.stanford.edu/cgi-bin/source/sourceResult?
choice=Gene&option=CLUSTER&criteria=Hs.434271).
While this putative gene is supported by a variety of clones and
splice variants, only two of the currently posted ESTs
(BX646189, BN413679) contain parts of the proposed first
exon, with the ATG site present only in the first of the two. OurFig. 2. (A) Alignment of translated PRCDORF producing a 54-amino-acid protein for
are completely conserved between the first two species, while 4 aa are replace
nonconservative, and the identically (.), strongly (*), and weakly (+) conserved pos
species is shown on the right. (B) Alignment of exon 1-coded protein sequence in 11 a
dimensional modeling of PRCD suggests the formation of an α-helix of approximate
gray) does not appear to influence the secondary structure.clone locates the ATG start codon of the human ORF 84 bp
upstream of the splice site at the end of exon 1, exactly as in the
dog. The human ORF ends with a TAA stop codon at position
20 of exon 3, as in the dog. In mouse a TAG is present at the
same position.
The murine 596-bp transcript (Accession No. DQ390337;
Fig. 1D) spans five exons and is partially homologous to a full-
length mouse RIKEN cDNA clone isolated from 16-day
cerebellum (AK137302). Our clone has a different profile in
the 5′ and 3′ ends; it is missing a putative 5′ exon and 200 bp of
the AK137302 3′UTR. We have not been able to amplify this
putative 5′ exon from mouse retinal cDNA, and the exon 1 we
have characterized is in agreement with GeneScan prediction
for the mouse genome draft, placing the ATG site 81 bp
upstream of the end of exon 1. We have identified an additional
splice variant that is missing part of exon 1 (data not shown),
indicating potential alternative splicing in the mouse. These
sites are not conserved in the dog or human.
Structure and conservation of PRCD
The overall nucleotide conservation of PRCD between dog,
human, and mouse (dog–man 81%; dog–mouse 78%; human–
mouse 78%) is slightly lower than previously observed for
comparisons between mammalian gene orthologs [20]. How-
ever, the conservation profile at the protein level suggests
functional importance, particularly for the first 24 aa coded for
by exon 1 (Fig. 2A). The SignalP 3.0 server (http://www.cbs.
dtu.dk/services/SignalP/) predicts a likely cleavage site between
aa 20 and aa 21, suggesting function as a signal peptide with a
C-terminal transmembrane domain; this conclusion is supported
by other prediction software (e.g., “DAS” transmembrane
prediction server). We identified the ortholog of canine PRCD
exon 1 in 14 different vertebrate species for which genomic
sequence is available (Fig. 2B), confirming the evolutionary
constraint of this peptide, which is predicted to form an α-helix
structure in a 3D model (Fig. 2C). According to the secondary
structure prediction methods used by the BIOINFO metaserver,human and dog; the mouse is missing a single amino acid (aa 10). The first 28 aa
d in the predicted mouse protein. Replacements are highlighted in gray if
itions are indicated underneath the sequence. Percentage of homology between
dditional species demonstrating absolute conservation of the first 4 aa. (C) Three-
ly 20 aa at the N-terminal end (ball and stick). The C2Y mutation (highlighted in
Fig. 3. (A) Example of a prcd-informative ECS pedigree showing cosegregation of haplotypes with the disease. GRB2, AANAT, and SEC14L are outside the candidate region, but a benign AANAT SNP is in complete
linkage disequilibrium with the disease in this breed [16]. (B) Restriction enzyme test shows complete digestion of the PRCD A allele with RsaI and of the G allele with ApaLI. (C) Assessment of the PRCD genotype by
pyrosequencing.
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555B. Zangerl et al. / Genomics 88 (2006) 551–563the C2Y mutation in the human and canine sequences (see
below) does not appear to change the predicted α-helical
conformation of the initial 15-aa fragment. PRCD could not be
identified in nonvertebrate species (e.g., Drosophila melano-
gaster, Arabidopsis thaliana, or any published insect genome).
We screened for potential transcription binding sites 1000 bp
upstream of the ATG using the consite algorithm [score
threshold of 80% (http://mordor.cgb.ki.se/cgi-bin/CONSITE/
consite)] or manually (CRX, NRL). Overall, 86, 74, and 74
motifs are located on the positive strand only in the dog, human,
and mouse sequence and represent binding sites for 32, 36, and
23 different factors, respectively. Thirteen transcription factors
are common to all three species (AML-1, ARNT, bZIP910,
E74A, Hen-1, Max, NF-Y, n-MYC, Snail, Sox5, Sox17,
Thing1-E47, USF). Pair-wise analysis of alignments, however,
identified only one Sox17 site, located approximately 50 bp in
front of the ATG, and CRX binding sites that were spatially
conserved (Supplementary Fig. 1, dark and light gray boxes,
respectively). The same comparative analysis suggests potential
involvement of CFI–USP and Snail as regulators through
binding sites in intron 1 of PRCD (data not shown). CRX
binding sites were also recognized in the potential 5′UTR of the
additional 11 species for which exon 1 sequence is available,
strongly suggesting the importance of this regulatory site. A
potential binding motif for another retinal regulator, NRL, was
found in the putative promoter region of the chicken, but could
not be identified in the other species.
Putative TATA boxes are located at position −565 in dog
and −593 in human (AATATT; Supplementary Fig. 1); a
second box could be present at −723 and −759 in the dog and
human, respectively, but is less conserved between species
(common motif ATATA), and the human might have a third
box at −803 (not shown in Supplementary Fig. 1 alignment).
Putative CAAT motifs are observed at −408 in the dog and at
−242 and −595 in human. However, none of these trans-
cription initiation sites could be identified in the mouse
sequence.
Mutation in PRCD causes retinal degeneration in dog and
human
Identification and segregation of the canine PRCD mutation
Retinal cDNA sequence comparison of the canine PRCD
ORF (Supplementary Table 1, primers 3 and 4) from 8.6-week
prcd-affected and 10.4-week normal dogs identified a single G
to A transition at nucleotide 5 of the coding sequence. This
mutation causes a cysteine to tyrosine change (C2Y) at the
second amino acid of the protein in the affected animal. The
causal association between this mutation and prcd was
established by: (a) consistent and stable segregation of the
mutation in the prcd reference colony; (b) segregation of the
mutation in well-maintained pedigrees of breeds included in
previous prcd breeding studies; (c) segregation of the mutation
in dog breeds for which the diagnosis of prcd was obtained by
the investigators (G.D.A., G.M.A.) and pedigrees were followed
over several generations; (d) observation of the prcdmutation in
breeds with a clinical diagnosis of retinal degenerationcompatible with prcd; (e) absence of the mutated allele from
breeds not segregating the prcd phenotype. Details of these
studies are presented below:
(a) We have maintained a reference colony segregating prcd
for more than 10 generations. The founder chromosomes
were from affected toy and miniature poodles (TP, MP
[9]). Affected chromosomes originating from Labrador
retriever (LR), Portuguese water dog (PWD), Nova Scotia
duck tolling retriever (NSDTR), Australian cattle dog
(ACD), and English cocker spaniels (ECS) were
introduced into the colony subsequently and segregate
the same phenotype. The affected haplotype present in
this colony has been identified [16] and shows complete
concordance with the phenotype. The prcd mutation is
included in this haplotype described by 98 polymorph-
isms in Supplementary Table 1 of the companion paper
[16] and does not show any discordance from inheritance
within the reference colony.
(b) We also have access to outside pedigrees from these
breeds in which prcd segregates. These animals were
screened for the disease-specific haplotype and canine
PRCDmutation. Complete concordance between affected
phenotype and genotype was confirmed for affected and
obligate carriers in ACD, ECS, LR, NSDTR, MP, PWD,
and TP using a restriction enzyme analysis (see Figs. 3A
and 3B for illustration). In addition, we have selected a
small subset of dogs from some breeds (ACD, LR, MP,
TP) that had a clinical retinal disease atypical for the
breed-specific form of retinal degeneration. For example,
these included dogs showing clinical signs much earlier
or later than the characteristic age of onset of prcd in the
breed, inflammatory retinopathy, or other clinical disease
features not considered characteristic of prcd. In all cases,
these dogs were found to be heterozygous or homozygous
normal at the disease locus. Sequence analysis using a
subset of markers from the prcd LD region confirmed
exclusion of prcd and suggested that the clinical disease
(s) present in these dogs were geno- or phenocopies.
(c) Pedigrees were available for four breeds of which three
were not included in the breeding studies [9]: American
cocker spaniel, American Eskimo (AE [21]), Chesapeake
Bay retriever, and Entlebucher mountain dog (EMD
[22]). With the exception of one dog, there was complete
concordance between the canine PRCD mutation and
affected and obligate carrier status. The exception was an
AE that was homozygous affected (A/A), but clinically
normal at 13 years. As the disease in this and some other
breeds, e.g., ECS, can occur at a much later age [2,9],
definite phenotypic diagnosis will require histologic
assessment after death of the animal.
(d) Selected samples of representative dog breeds that
showed a retinal disease that appeared to be clinically
compatible with prcd were collected by the investigators
or provided by colleagues. These included the following
breeds: Chinese crested (CC), silky terrier (ST), Finnish
lapphund (FL), Kuvasz, Lapponian herder, and Swedish
556 B. Zangerl et al. / Genomics 88 (2006) 551–563lapphund. The homozygous G → A mutation in canine
PRCD was found in all five breeds. Further analysis of
these breeds is currently in progress.
(e) To establish that the A allele is not just a rare SNP in the
population that has been concentrated in a few selected
breeds, high-throughput pyrosequencing analysis (Fig.
3C) was used to screen 1120 samples from unrelated dogs
from two groups: (i) 1007 samples from 37 breeds with a
non-prcd form of retinal degeneration for which dogs of
known phenotype were tested; in several of these breeds,
the molecular basis of the retinal disease was known and
the genotype at the disease locus established (Supple-
mentary Table 2); (ii) 113 samples of unrelated dogs from
54 breeds without known retinal disease (Supplementary
Table 3). All 1120 dogs tested from 91 different breeds
were homozygous normal (G/G) at nucleotide 5 of canine
PRCD. Furthermore, 24 red and 6 gray wolves also were
tested, and all were homozygous normal (G/G) at the
mutation locus.
In summary, the canine PRCD mutation has been observed
in 18 individual dog breeds or breed varieties (Table 1) to date
and was confirmed to cause disease in the homozygous state.
The disease-causing allele was never observed in dogs or breeds
confirmed not to segregate prcd.
Mutation identification and screening in human populations
We have found seven different human PRCD sequence
variations in a total of 1863 patients, most of whom were
clinically diagnosed with RP or allied retinal degenerations
(Table 2). Of these, 4 were found in the heterozygous state in the
noncoding regions of the gene and appeared unlikely to
represent disease-causing variations. One patient with auto-
somal recessive RP (arRP) showed a G → A transition in the
heterozygous state at 88 bp of the coding sequence. This
variation would be expected to cause a conservative substitution
of methionine for valine at aa 30 of the PRCD protein (V30M).Table 1
Breeds affected by prcd
Abbreviation Breed
ACD Australian cattle dog
ACS American cocker spaniel
AE American Eskimo
CBR Chesapeake Bay retriever
CC Chinese crested
ECS English cocker spaniels
EMD Entlebucher mountain dog
FL Finnish lapphund
KU Kuvasz
LH Lapponian herder
LR Labrador retriever
MP Miniature poodle
NSDTR Nova Scotia duck tolling retriever
PWD Portuguese water dog
SL Swedish lapphund
ST Silky terrier
STCD Australian stumpy tail cattle dog
TP Toy poodleDNA sequencing of the entire human PRCD coding sequence
in this patient failed to detect a second sequence variation. The
heterozygosity of the variation in this patient, coupled with the
conservative nature of the predicted change in the protein,
makes it difficult to assert that this variation causes human
retinal disease even though the change was not observed in the
control population (215 individuals; Table 2).
Another transition (C → T in the 49th nucleotide of the
coding sequence, predicting the substitution of cysteine for
arginine in codon 17, R17C) was observed in the heterozygous
state in one RP patient of Indian origin, but was also observed in
the heterozygous state in five members of the Indian/Pakistani
control group. Bidirectional DNA sequencing was used to
examine the entirety of the human PRCD coding sequence in
the RP patient with the R17C change, and no other variations
were detected. This result, combined with the high frequency of
occurrence (5% of all alleles) of the variation in the ethnic
control samples, makes it likely that it represents a non-disease-
causing ethnic-specific polymorphism.
In contrast, a woman from Bangladesh with arRP was found
to harbor a G→A transition in the fifth nucleotide of the human
PRCD coding sequence, which would be predicted to result in a
substitution of tyrosine for cysteine (C2Y) in the second amino
acid of the protein. This is the identical mutation at both the
DNA and the protein levels that was observed in prcd-affected
dogs. The patient was 32 years of age when examined at the
University of Iowa. She was born in Bangladesh and first
noticed difficulty seeing at night as a small child. Her family
history was significant for four unaffected siblings, one brother
who became blind at a young age, and two other siblings still
living in Bangladesh with an uncharacterized vision problem.
Her parents were first cousins and had normal vision. The
patient's best corrected visual acuity was 20/70 in the right eye
and hand motions in the left eye with a manifest refraction of
−3.75+ 1.00×180 in the right eye and −2.00 sphere in the left
eye. Slit-lamp examination revealed clear corneas and anterior
chambers that were deep, clear, and quiet. The lenses were clear,
and there were no vitreous cells. Analysis of the papillary
response revealed a 0.9 log unit relative afferent papillary
defect. Goldmann perimetry showed a greater loss of sensitivity
in the left eye than in the right (Fig. 4A). Fundus examination
revealed optic discs with fairly normal color, but markedly
attenuated arterioles (Fig. 4B). There was extensive bone-
spicule-like pigmentation in all four quadrants of both eyes,
densest at the equator, and this intraretinal pigment was
admixed with lighter colored deposits at the level of the retinal
pigment epithelium. There were also small patches of geo-
graphic atrophy near fixation in both eyes. Ganzfeld electro-
retinography was performed, but no responses could be
recorded from either eye under any stimulus condition.
Expression and function of the PRCD gene
Expression profile of canine PRCD in normal and mutant
animals
Transcription of canine PRCD was examined by northern
analysis using probes specific for either exon 1 or exons 2–4
Table 2
Human PRCD sequence changes observed in the heterozygous (het) or homozygous (hom) state in patients with RP, Leber congenital amaurosis (LCA), cone-rod
dystrophy (CRD), or Usher syndrome (USH) and in normal Caucasian (NML) and Indian/Pakistani (I/P NML) control populations
Disorder RP LCA CRD USH NML I/P NML
Number of patients/controls 1241 283 224 115 166 49
Position Sequence change aa change
−106 het C → T 1 0 0 0 0 0
−40 U het T→ C 1 0 0 0 0 0
5 hom TGC→ TAC Cys2Tyr 1 0 0 0 0 0
49 het CGC→ TGC Arg17Cys 1 0 0 0 0 5
88 het GTG→ ATG Val30Met 1 0 0 0 0 0
*57 U het C → G 1 0 0 0 0 0
*80 het G→ A 1 0 0 0 0 0
* indicates the nucleotide 3′ of the termination codon; U indicates that the nucleotide is within the UTR.
557B. Zangerl et al. / Genomics 88 (2006) 551–563(Fig. 5A). The same level of expression was observed in retinas
from normal and prcd-affected dogs and showed two distinct
retinal transcripts of 2 and 6.5 kb. Experiments with a probe
specific for the 3′UTR located in the contig 1131 sequence
yielded the same results (data not shown). The same transcripts
were observed in RPE/choroid, but the level of expression in
other tissues was too low for detection. RT-PCR amplification
using primers located in exons 1 and 4 (Supplementary Table 1,
primers 1 and 31) showed low levels of canine PRCD
expression in a variety of tissues (data not shown).
To quantify the expression profile of canine PRCD, we
performed quantitative real-time PCR (qRT-PCR) on different
tissues of a 16-week-old normal dog for two probes: one specific
for exon 1 and the other spanning parts of exons 2 and 3. Results
are shown for the exon 1 probe only, as no significant differences
between the two probe sets were found. Relative expression was
calculated against an 18S probe as the difference of cycles
leading to amplification. In addition, retinal samples from prcd-
affected dogs of various ages (10, 16, and 23 weeks; 2 and
3 years) also were analyzed by qRT-PCR. Comparison of canine
PRCD expression in the normal vs. prcd-affected retina showedFig. 4. Clinical assessment of an arRP patient of Bangladesh birth at age 32. (A) The G
I4e isopter (shown in blue) is limited to less than 5°. There is persistence of a tempo
photograph of the right eye of the patient centered on the inferotemporal vascular arcad
attenuated. Typical bone-spicule-like pigmentation can be seen admixed with pale de
retinal pigment epithelium can be seen adjacent to the fovea (the fovea can be recogno significant changes in expression with age or disease stage
(Fig. 5B). Expression in spleen, liver, and pancreas was
insufficient for quantification, and no expression was observed
in the lung (data not shown). In comparison to normal retina,
there was significantly lower expression in all other tissues
tested (Fig. 5B); there was ∼6.5-fold lower expression in RPE/
choroid, 16-fold decrease in kidney, and 100- to 1000-fold
decreases in other tissues. Even though expression levels for
cerebrum represented a pooled sample of frontal, occipital, and
temporal lobes, analysis of individual samples showed compar-
able low levels of expression (data not shown).
Laser capture microscopy was used in the normal retina to
compare canine PRCD expression specifically in the RPE,
photoreceptor, and ganglion cell layers. Comparable expression
in all three layers suggests that this gene has uniform expression
in many retinal cell types and is not photoreceptor specific or
enriched (Fig. 5C).
Expression of wild-type and mutant human PRCD in COS cells
His-tag localization was performed on COS cells transfected
with either wild-type or mutant (C2Y) human PRCD. Whereasoldmann visual field of the right eye shows complete loss of the I2e isopter. The
ral island that is sensitive only to the V4e target (shown in purple). (B) Fundus
e. The optic disk is of fairly normal color, but the retinal arterioles are extensively
posits at the level of retinal pigment epithelium. Small patches of atrophy of the
nized as the region of darker pigmentation to the left of the optic nerve head).
Fig. 5. Expression profile of canine PRCD. (A) Northern analysis with probes specific for exon 1 and exons 2–4 of canine PRCD identifying two distinct transcripts (2
and 6.5 kb) expressed in the normal and prcd-affected retinas (R, 10.4 weeks; R prcd, 8.6 weeks). No signal is present in normal or affected brain (B, 15.7 weeks; B
prcd, 7.7 weeks) or normal spleen (S, 22.1 weeks). The same transcripts are expressed at lower levels in the RPE/choroid (RPE) compared to retina. β-Actin was used
as loading control. (B) qRT-PCR results show high expression in the retina compared to other tissues. An expression profile (shown as relative expression against 18S)
was established for a normal dog at 16 weeks of age (center) and is similar to the expression levels found in affected retinas of different ages (left). Relative expression
normalized against retina provides fold reduction in the expression between tissues (right). (C) Individual retinal layers (RPE, photoreceptor, and ganglion cell layers)
from a normal eye were isolated with a laser capture microscope (respective regions are illustrated by octagons below black bars) and analyzed by qRT-PCR. No
significant differences in expression were observed between the layers.
558 B. Zangerl et al. / Genomics 88 (2006) 551–563the wild-type fusion protein was distributed diffusely through-
out the cytoplasm (Figs. 6A and D), in the majority of
transfected cells the mutant protein was present in spherical
aggregates within the cytoplasm (Figs. 6E and 6H). The
distribution of the wild-type protein did not substantially
overlap with that of actin filaments in the cytoplasm, but did
extend into cell processes and showed greatest labeling around
the nucleus.
Discussion
A combination of LD mapping [16] and the characterization
the canine retinome [18] identified the 3′ end of a novel retinalgene. This gene was subsequently cloned in dog, human, and
mouse, and a mutation that causes canine and human retinal
degeneration was found. The gene has been given the
preliminary name of “progressive rod–cone degeneration”
with the gene symbol “PRCD” (approved by the HUGO Gene
Nomenclature Committee).
PRCD has a predominant transcript of 671 bp in the dog
retina and encodes a conserved ORF (78–81% conservation).
GenBank entries of human and murine transcripts, as well as
potential alternative splicing identified in the dog, suggest
alternative splice variants for this gene, and some of these have
been characterized in dogs (data not shown). However, we
could not identify usage of additional 5′ exons in any of the
Fig. 6. Immunocytochemical localization of (A) wild-type and (E) mutant PRCD in COS-7 cells. No colocalization was observed with phalloidin-labeled actin (B, F)
or nuclei stained with DAPI (C, G) in the merged images (D, H). Localization of the His tag was present in a diffuse weblike distribution in most cells transfected with
the wild-type construct (A, D), whereas labeling was generally concentrated in vesicular profiles in the cytoplasm in cells transfected with the mutant construct (E, H).
Magnification: 460×.
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correct sequence was confirmed, and the final ORF was chosen
based on conservation between species. PRCD encodes a 54-aa
protein in dog and human; in mouse it is 53 aa as 3 in-frame
coding nucleotides (Nos. 28–30) are missing from exon 1. The
conservation of potential regulatory elements and binding sites
further suggests the correct positioning of the proposed ORF
(Supplementary Fig. 1). Three CRX binding sites are located
just upstream of the ATG site in dog, human, and mouse; this
factor is thought to drive photoreceptor expression [23,24]. A
large number of potential transcription factor binding sites could
be identified within the 5′UTR and intron 1, and 13 of these
were common to the three species investigated. However, only
the Sox17 site showed high positional conservation, suggesting
that this might be one of the PRCD-interacting genes even
though this transcription factor predominantly regulates the
transcription of endodermal genes [25,26]. Additional studies
currently are under way to assess further the regulation and
function of PRCD.
Comparison of the cDNA between prcd-affected and normal
dogs identified a G to A substitution at position 5 of the canine
PRCD ORF that causes a C2Y change in the translated protein.
No other change within the available RPCI81 BAC 10-M13
sequence was found that segregated with the disease phenotype.
Subsequent screening of the canine PRCD mutation indicated
the absence of the mutated allele (A) in 1120 dogs from 91
different breeds not diagnosed with the prcd form of PRA as
well as 24 red and 6 gray wolves (Supplementary Tables 2 and
3). As well, breeds identified to segregate the prcd haplotype
[16] showed complete concordance between the mutated allele
in the homozygous state and the clinical diagnosis of prcd. The
high number of dogs investigated supports the association
between mutation and disease phenotype, and this is particu-larly important when identifying a mutation in a novel gene of
unknown function.
Some exceptions in the investigated breeds, however, were
noted and bear mentioning. We have identified dogs with retinal
degeneration that were homozygous for the normal (G) allele.
Labrador retrievers with advanced retinal degeneration at
<1 year rather than 6–8 years represented age outliers for the
breed-specific disease [2]. Others, e.g., CC, ST, and ACD, had
retinal degeneration that was clinically similar to prcd, either in
age of onset or in clinical appearance, but were homozygous
normal for canine PRCD. It is likely that these retinal
degenerations, if not acquired phenocopies, are caused by
mutations in different retinal disease genes, an issue that we
have previously reported for the Norwegian elkhound and
miniature schnauzer breeds (see [2] for review). For all of the
discordant individuals for which haplotype analysis was carried
out, we were able to exclude the segregating chromosomes from
association with prcd [16].
An AE dog was of particular interest because she typed
homozygous affected for prcd (A/A), but did not show clinical
signs at 13 years. Both chromosomes were confirmed to
produce the disease phenotype in affected relatives through
extended haplotype analysis. Such a delay in onset of disease is
not surprising given the variation in disease onset and
progression that occurs in some breeds with prcd [9]. For
example, in the ECS we have found the age of early diagnosis to
vary from 3.1 to 13.5 years in dogs having the same mutation in
canine PRCD (OptiGen LLC, unpublished information).
Comparative analysis of the genetic background between
different phenotypic variants of prcd has been proposed to
identify the genetic modifiers. Such studies will contribute to
our understanding of PRCD function and the molecular
mechanisms of disease.
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ortholog, and the subsequent screening of patients clinically
diagnosed with various forms of retinal disease, led to the
identification of a patient that is homozygous for the same
sequence variation, at both the nucleotide and the amino acid
level, as found in prcd dogs. This coincidence may suggest that
function-altering sequence variations that occur elsewhere in this
gene are likely to have a phenotype different from that of the
patients that were screened in this study. The one RP patient
identified with a PRCD mutation had advanced disease in the
fourth decade of life withmarked constriction of the visual fields,
a nonrecordable electroretinogram, and extensive bone-spicule-
like pigmentation. Such advanced disease is similar to what is
observed in most canines affected with prcd at a comparable age
[2]. Although the patient has a family history of vision problems,
the remaining family members still live in Bangladesh, and the
acquisition of additional samples and phenotype characterization
of family members has been difficult. We are hopeful these data
will become available soon. Although this study shows that
human PRCD mutations are an extremely rare cause of retinitis
pigmentosa in patients ascertained in North America, it will
require further study to determine whether mutations in this gene
are responsible for a larger fraction of this disease in Bangladesh
or in other Asian populations.
Expression of PRCD indicates two main retinal transcripts of
2 and 6.5 kb using northern analysis, both of which contain
exons 1–4, as well as the originally identified 3′UTR region.
The expression of canine PRCD was determined by qRT-PCR
and showed that the highest level is in retina followed by RPE/
choroid and that other tissues have very low or negligible levels.
However, the use of laser microscopy to isolate specifically
different retinal cell layers allowed us to quantify more precisely
the contribution of each to the total canine PRCD mRNA pool.
This showed that there was approximately equal expression in
the RPE, photoreceptor, and ganglion cell layers, thus
explaining why there is no decrease in canine PRCD expression
as the photoreceptor cells are lost with disease progression. Data
from immunocytochemical subcellular localization experiments
suggest that the mutant form of the protein exhibits a distinct
pattern of localization into spherical profiles within the
cytoplasm, and we posit that this altered localization may
impair function and/or its interactions with other proteins in the
affected human and canine retina.
As can be appreciated, it is extremely difficult to assess the
function of a protein that has not been known thus far and does
not belong to any known gene family. To date, we have shown
that PRCD is causally associated with retinal degeneration in
dog and human. As well, in silico analysis strongly suggests the
functional importance of this gene based on the high
conservation in vertebrate species. Our working hypothesis
includes the formation of an α-helix involving the first 24 aa of
PRCD that might contain a transmembrane segment; partial
homology of this region to other confirmed or predicted
bacterial proteins (e.g., AAS62120, ABD02230) highly sup-
ports this hypothesis. The first 4 aa, totally conserved in 14
vertebrate species analyzed, are not predicted to be part of the
transmembrane domain. They are likely to play an importantrole as the recognition site for interacting proteins. Therefore,
the described mutation in the highly conserved second amino
acid would significantly influence the function of PRCD. The
nature of the mutation and the observed change in the
localization are concordant with changes in the long-term
viability of the retina rather than a fast-acting developmental
disorder. However, the exact disease mechanism will require a
series of further studies.
The importance of this novel gene, PRCD, for maintenance
of rod photoreceptor structure, function, and/or survival is
attested to by its high level of conservation in vertebrate species.
The significance of this conservation, absolute for the first four
codons, is underscored by the causal association of the C2T
mutation reported here with hereditary retinal degeneration in
both dogs and humans. The apparent absence of a homologous
gene in invertebrates suggests that the function of the PRCD
protein is critically important to those aspects of photoreceptor
structure or metabolism unique to vertebrate visual cells. As
these issues yield to further studies, they should provide new
insights into vertebrate photoreceptor evolution, as well as into
the mechanisms of photoreceptor health and disease.Materials and methods
FISH mapping
Four milliliters of peripheral blood containing 0.2 ml preservative-free
heparin was incubated with 31 ml of complete medium for 96 h at 37°C [27].
After incubation, 5 ml of medium was aspirated, and cells were arrested with
0.2 ml colcemid (10 μ/ml) during a 1.5-h incubation. Chromosomal spreads
were prepared on slides using standard hypotonic solution and methanol/acetic
acid fixation, and chromosome painting was performed [28] using RPCI81 BAC
clones specific to CFA9 (No. 189-B1) or included in the physical map (No. 429-
O8) of the prcd interval [15]. FISH images of probes hybridized onto G-banded
metaphases were captured using the ISIS software (In Situ Imaging System;
Metasystems) with a Paco CCD camera mounted on an Aristoplan (Leitz)
microscope [28].
Protein structural analysis
Three-dimensional (3D) models for PRCD sequences were built using the
MODELLER program [29–31] with (a) experimentally determined structures
for the templates extracted from the Protein Data Bank and (b) sequence
alignments obtained from the BIOINFO metaserver [32]. The pair-wise
alignments produced by the metaserver were assigned relatively low scores
(low level of certainty) by the 3-D-Jury tool. However, the set of highest score
alignments points to structures having a short α-helical fragment at the N-
terminal end of the protein. 3D models for all the sequences were generated by
comparative protein modeling through satisfaction of spatial constraints with
the MODELLER program, minimizing infringements of distance and dihedral-
angle restraints from the template structures.
Study samples
Research dogs were maintained at the Retinal Disease Studies Facility in
Kennett Square, Pennsylvania, under cyclic light conditions, and prcd status
was established using morphological, ERG, or genetic criteria [14]. The dogs
represented several breeds in which prcd allelism had been established through
interbreed crosses [2,9]: ECS, LR, MP, and TP. Allelism with prcd has also been
established for ACD, NSDTR, and PWD [16]. In addition to the colony-derived
research dogs, we obtained blood samples and clinical records of dogs submitted
by their owners or other scientists directly to our lab or through OptiGen, LLC.
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the investigators (G.M.A., G.D.A.) carried out the clinical evaluations.
Euthanasia with a barbiturate overdose was performed at a single time of the
day (10:00 AM) to prevent fluctuation in the abundance of retinally expressed
genes, and retinas were isolated from the eyecup within 1–2 min of death. Other
tissues were obtained within 5–10 min, and all tissues were flash frozen in liquid
nitrogen and stored at −80°C until used. The human retina was isolated from a
76-year-old female donor 8 h postmortem and obtained through the National
Disease Research Interchange. After isolation, it was snap frozen in liquid
nitrogen and processed as described. Neural retina from C57BL/6 mice were
pooled to obtain sufficient tissue for cDNA amplification of the murine Prcd.
A total of 1863 unrelated human patients with a clinical diagnosis of heritable
photoreceptor disease were studied. All individuals provided written informed
consent. Approximately a third of these patients were ascertained in the Retina
Clinic of theUniversity of Iowa,while the remainderwas ascertained by inherited
retinal disease specialists elsewhere in the United States. One thousand two
hundred forty-one patients were diagnosed with RP, 283 with Leber congenital
amaurosis, 224 with cone–rod dystrophy, and 115 with Usher syndrome. All of
these patients had been screened previously for mutations in one or more genes
known to cause their diseases (RetNet—Retinal Information System; http://www.
sph.uth.tmc.edu/RetNet/), and none of them had been found to harbor a plausible
disease-causing variation in a known retinal disease gene. Normal controls from
the University of Iowa consisted of 166 subjects (general population controls) of
mixed ages who had no personal or family history of heritable retinal disease.
Over 80% of this group described themselves as “Caucasian.” The second group
consisted of 49 unrelated control subjects from India and Pakistan.
Sample preparation
Total RNAwas isolated using Trizol extraction followed by treatment with
DNase (1 unit RQ1 DNase; Promega), if used for qRT-PCR, and protection with
RNase inhibitor (Roche Applied Science). Double-stranded cDNA was
synthesized using the Thermoscript RT-PCR kit (Invitrogen) with random
hexamer primers. Amplification was obtained under standard conditions
(Supplementary Table 1, primers 1, 2, and 11; Accession Nos. DQ390332,
DQ390333), and extension of cDNA sequence by RACE was obtained from a
10-week normal retina through the SMARTRACE cDNA amplification kit
(Clontech) following the manufacturer's protocol (Supplementary Table 1,
primers 5–8). RT-PCR using primers from exons 1 and 4 (Supplementary Table
1, primers 9 and 10) confirmed the main transcript (695 bp, four exons;
Accession No. DQ390330), but suggested a second transcript, which does not
splice out intron 1 (Accession No. DQ390331). Additionally, primers located
specifically in exon 2 and the predicted exon 5 of canine PRCD (Supplementary
Table 1, primers 12 and 13) yielded three splice variants (796, 763, and 509 bp),
utilizing different potential splicing sites between exons 4 and 5 (Accession Nos.
DQ390334, DQ390335, DQ390336). All amplicons were cloned into the pCR
2.1-TOPO vector (Invitrogen) following the manufacturer's protocol and stored
in glycerol. Selected clones were sequenced for insert verification. DNA was
extracted from spleen or blood using the QIAmp DNA Mini Kit (Qiagen). All
RNA and DNA samples were evaluated on a 1% denaturing agarose–
formaldehyde or agarose gel prior to use, and level of purity and concentration
was measured with a spectrophotometer.
Restriction enzyme analysis
Amplification from genomic DNA with primers 3 and 17 (Supplementary
Table 1) at an annealing temperature of 58°C under conditions described above
resulted in a 512-bp PCR product. Restriction enzyme digestion performed in a
25-μl reaction on 500 ng PCR product with RsaI resulted in 396- and 116-bp
bands in the presence of the mutated (A) allele; digestion with ApaLI resulted in
397- and 115-bp bands in the presence of the normal (G) allele. The genotypes
resulting from the digestion were visualized on 6% polyacrylamide gels.
Pyrosequencing
High-throughput screening for the mutant (A) and normal (G) PRCD alleles
was done by Pyrosequencing (Biotage). PCR was performed on isolated DNAwith primers (Supplementary Table 1; primer 18 and biotin-labeled primer 19)
under standard conditions with 1.5 mMMgCl2 at 55°C annealing temperature in
35 cycles, checked on a 2% agarose gel, and purified with Streptavidin
Sepharose High Performance Beads (Amersham). Primer 20 was added to
initiate the reaction, and primer elongation was achieved and recorded on a
Pyrosequencer PSQ 96MA using the PSQ 96 SNP reagent kit (Biotage).
Human PRCD screen
DNA was extracted from peripheral blood according to a previously
described protocol [33]. Samples from 1863 patients and 215 controls were
screened for variations in the whole coding sequence of PRCD using single-
strand conformational polymorphism (SSCP) analysis as previously described
[34]. To conserve DNA, the 49 Indian/Pakistani control samples were screened
for variations in exon 1 only. All samples exhibiting an abnormal electrophoretic
pattern by SSCP were further characterized using automated bidirectional
sequencing on an ABI Model 3730 using the BigDye version 3 chemistry
(Applied Biosystems).
Northern analysis
Samples were loaded on a 1% agarose–formaldehyde denaturing gel, and
3 μg of 0.24–9.5 kb RNA ladder was used as a size marker (Invitrogen). The gel
ran with continuously circulating 1× Mops running buffer (Ambion) for 16 h at
21 V. After three 5-min washes in DEPC-treated water, 20 min in 0.05 N NaOH,
and a 15-min soak in 10× SSC, transfer to a nylon-based membrane
(GeneScreen Plus, NEN Life Science) was done with 10× SSC buffer using a
standard protocol. Full transfer was confirmed by exposing the gel to UV light.
The membrane was washed in 2× SSC for 2 min, and RNAwas cross-linked to
the membrane (exposure was 0.12 J/cm2; Stratalinker UV Crosslinker).
Northern probes were amplified from cDNA clones and labeled with
[α-32P]dCTP using the RadPrime DNA labeling system (Invitrogen).
Prehybridization and hybridization were carried out with ExpressHyb solution
(Clontech) at 68°C for 30 min. Hybridization was carried out at 68°C for 16–
18 h, and the blots were rinsed several times with 2× SSC, 0.05% SDS; the
washes with the same solution were done twice with continuous agitation for
40 min. Then the blot was washed with 0.1× SSC and 0.1% SDS with
continuous shaking at 50°C for 40 min with one change of fresh solution.
Blots were exposed to X-ray film at and 70°C for 24–96 h with two
intensifying screens. Loading control was achieved by hybridizing a canine-
specific β-actin (Z70044) probe to the membranes under the same conditions
and exposure to X-ray film for 4 h.
Quantitative real time PCR
Expression profiling of PRCD was done on a 7500 Real Time PCR System
(Applied Biosystems) with two TaqMan assays. Probes and primers were
designed using the Primer Express Software (Applied Biosystems) resulting in
two primer sets. One produced a 55-bp product specific for exon 1
(Supplementary Table 1, primers 24 and 25, probe 26) and the second a 63-bp
product spanning the exon 2 and 3 junction (Supplementary Table 1, primers 21
and 22, probe 23). TaqMan PCR amplification was performed in a two-step RT-
PCR, reverse transcribing the RNA first with the TaqMan reverse transcription
reagents (Applied Biosystems) followed by amplification of the target sequence
using the TaqMan Universal Master Mix with the specific probe sets. Gene
expression was evaluated through relative quantification against an 18S
endogenous control (Hs99999901_s1; Applied Biosystems).
Laser capture microscopy
Glass slides with 10-μm frozen sections of normal canine retina (16 weeks)
fixed in 4% paraformaldehyde and embedded in OCT [35] were thawed for 20 s
and subsequently dehydrated through serial immersion in 70, 95, and 100%
EtOH for 1 min each, followed by 2×5 min in xylene. Laser capture was
performed with a PixCell II laser capture microdissection apparatus (Arcturus)
on CapSure HS LCM Caps (Arcturus) at 50 mW, capturing a total of 3024
ganglion, 2525 RPE, and 1850 photoreceptor shots. RNAwas isolated with the
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OA RNA amplification kit (Arcturus), both following manufacturer's protocols.
A final cDNA concentration of ∼15 ng/μl was obtained based on spectro-
photometer measurement for each cell class isolated, and 1 μl was used for qRT-
PCR as described.
Protein expression and localization
COS-7 cells (American Type Culture Collection, Manassas, VA, USA) were
maintained in Dulbecco's modified Eagle's medium [with 10% (v/v) fetal calf
serum, 1% penicillin/streptomycin, L-glutamine, sodium pyruvate, nonessential
amino acids, Hepes, and gentamycin]. Prior to transfection, cells were split and
grown on coverslips in six-well plates. Transfection of expression vectors
(pCDNA3.1v5His; see above) containing either the wild-type human PRCD
gene or the C2Y mutant were mediated using Lipofectamine 2000 (Invitrogen)
in Opti-MEM 1 (Gibco) for 48 h according to the manufacturer's instructions.
Cells were fixed for 5 min in 4% formaldehyde (prepared from
paraformaldehyde) in 10 mM phosphate-buffered saline (PBS), pH 7.4.
Coverslips were then washed in PBS, and their top surfaces were covered
with blocking solution (1 mg/ml bovine serum albumin in PBS) for 15 min.
Following a brief rinsing step in PBS, coverslips were then incubated with anti-
His tag primary antibody (Invitrogen) at a concentration of 6 μg/ml in PBS with
0.1% Triton X-100 for 1 h. After being rinsed with PBS, coverslips were
incubated with an anti-mouse secondary antibody conjugated to Alexa-546
(Invitrogen) at a 1 to 200 dilution for 30 min. Coverslips were washed and then
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and with Alexa 488-
conjugated phalloidin, an actin-binding dye, diluted 1 to 200 (Invitrogen).
Coverslips were then placed on glass slides, mounted with Aquamount (Ted
Pella), and photographed with a BX41 fluorescence microscope (Olympus).Acknowledgments
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